Companies › Gilead · Global Markets & Policy
Gilead Sciences, Inc.
- Nasdaq: GILD
US biotechnology company known for HIV, liver disease, cancer and COVID-19 treatments.
Gilead quarterly results and earnings history →
Insider trades (Form 4)
Last 120 days: open-market sales $18.4M, purchases $0. All Gilead insider transactions →
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Daniel Patrick O'Day Chairman & CEO, Director | Open-market sale 10b5-1 plan | 12,000 | $147.72 | $1.8M | Form 4 ↗ |
| Oct 1, 2026 | Daniel Patrick O'Day Chairman & CEO, Director | Open-market sale 10b5-1 plan | 3,000 | $148.63 | $446K | Form 4 ↗ |
| Sep 15, 2026 | Andrew D Dickinson Chief Financial Officer | Open-market sale 10b5-1 plan | 3,000 | $145.29 | $436K | Form 4 ↗ |
| Sep 15, 2026 | Johanna Mercier Chief Comm & Corp Aff Officer | Open-market sale 10b5-1 plan | 1,600 | $143.69 | $230K | Form 4 ↗ |
| Sep 15, 2026 | Johanna Mercier Chief Comm & Corp Aff Officer | Open-market sale 10b5-1 plan | 800 | $144.46 | $116K | Form 4 ↗ |
Key financials
| Metric | FY to Dec 2022 | FY to Dec 2023 | FY to Dec 2024 | FY to Dec 2025 |
|---|---|---|---|---|
| Revenue | $27.3B | $27.1B | $28.8B | $29.4B |
| Operating income | $7.3B | $7.6B | $1.7B | $10.0B |
| Net income | $4.6B | $5.7B | $480.0M | $8.5B |
| Diluted EPS | $3.64 | $4.50 | $0.38 | $6.78 |
Fiscal years, from annual reports (10-K / 20-F). Source: SEC EDGAR (XBRL company facts), retrieved 2026-10-14. Verify figures against the original filings.
Recent filings
- 2026-08-06 · 10-Q
- 2026-08-04 · 8-K — Results of operations
- 2026-05-20 · 8-K — Material agreement; New financial obligation; Other events
- 2026-05-07 · 10-Q
- 2026-05-07 · 8-K — Results of operations
- 2026-05-04 · 8-K — Shareholder vote results
- 2026-04-28 · 8-K — Regulation FD disclosure; Other events
- 2026-03-20 · DEF 14A
Source: SEC EDGAR, retrieved 2026-10-14. Filing types explained: 8-K, 10-Q, 10-K, 20-F / 6-K.
Not investment advice. This page lists official filings and our reports for reference. SignalStack does not rate securities or recommend buying or selling anything.